Global Primary Immunodeficiency Disease Market Size to Exceed USD 12.80 Billion by 2033: Forecast Analysis Report

Global Primary Immunodeficiency Disease Market Size to Exceed USD 12.80 Billion by 2033               

According to a research report published by Spherical Insights & Consulting, The Global Primary Immunodeficiency Disease Market Size is Expected to Grow from USD 7.11 Billion in 2023 to USD 12.80 Billion by 2033, at a CAGR of 6.06% during the forecast period 2023-2033. 

Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Primary Immunodeficiency Disease Market Size, Share, and COVID-19 Impact Analysis, By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others), By Treatment (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell/Bone Marrow Transplantation, Gene Therapy, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.

The primary immunodeficiency disease (PIDD) market refers to the global industry focused on the diagnosis, treatment, and management of primary immunodeficiency diseases as well as genetic disorders that impair the immune system’s ability to fight infections. This market includes pharmaceuticals, biologics, immunoglobulin therapies, stem cell transplants, diagnostics, and supportive care, driven by advancements in biotechnology, increasing awareness, and improved healthcare access. Furthermore, the market for global primary immunodeficiency disease is driven by an increase in the prevalence of the disease, mounting newborn screening programs, advancements in diagnostic technology, and increasing patient awareness and doctor awareness. On the other hand, increased government programs, an improved healthcare environment, mounting immunoglobulin therapies demand, and constant research & development for innovative treatment are spurring the market to grow within the forecasted period. However, the high treatment costs, limited awareness, delayed diagnosis, lack of advanced healthcare infrastructure in developing regions, and stringent regulatory approval processes are key restraining factors of the global primary immunodeficiency disease market.

The antibody deficiency segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.              

On the basis of the disease, the global primary immunodeficiency disease market is divided into antibody deficiency, cellular immunodeficiency, innate immune disorders, and others. Among these, the antibody deficiency segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is propagated to its high prevalence among primary immunodeficiency diseases, increasing awareness, and advancements in diagnostic techniques. Rising demand for immunoglobulin therapies, improved treatment accessibility, and growing research initiatives further contribute to its significant CAGR growth during the forecast period.

The immunoglobulin replacement therapy segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period.

On the basis of the treatment, the global primary immunodeficiency disease market is divided into immunoglobulin replacement therapy, antibiotic therapy, stem cell/bone marrow transplantation, gene therapy, and others. Among these, the immunoglobulin replacement therapy segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period. The segmental growth is expansion to its effectiveness in managing primary immunodeficiency diseases, rising demand for intravenous and subcutaneous immunoglobulins, and growing patient awareness. Additionally, advancements in biologics, increasing healthcare expenditure, and improved access to treatment are driving its substantial CAGR growth over the forecast period.

North America is projected to hold the largest share of the global primary immunodeficiency disease market over the forecast period.

North America is projected to hold the largest share of the global primary immunodeficiency disease market over the forecast period. The regional growth is attributed to its advanced healthcare infrastructure, high diagnosis rates, and strong presence of key pharmaceutical players. Favourable reimbursement policies, increasing awareness, and rising adoption of immunoglobulin therapies further support market growth. Additionally, continuous research and development efforts drive innovation in treatment options.

Asia Pacific is expected to grow at the fastest CAGR growth of the global primary immunodeficiency disease market during the forecast period. The regional growth is attributed to rising awareness of primary immunodeficiency diseases, improving healthcare infrastructure, and increasing healthcare investments. The expanding patient population, growing access to advanced treatments, and government initiatives supporting rare disease management further drive market growth. Additionally, increased research and development activities enhance treatment options in the region.

Company Profiling

Major vendors in the global primary immunodeficiency disease market are Baxter International, Inc., CSL Behring LLC, Takeda Pharmaceutical Company Limited, Octapharma AG, Biotest AG, Grifols S.A., Kedrion Biopharma Inc., Bio Products Laboratory Ltd., LFB S.A., ADMA Biologics, Astellas Pharma Inc., Abbott Laboratories and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In April 2024, the FDA approved X4 Pharmaceuticals' mavorixafor, also known as Xolremdi, to treat WHIM syndrome, a rare primary immunodeficiency.  The CXCR4 receptor antagonist mavorixafor lowers infection rates and increases white blood cell counts in patients.  It significantly increased neutrophils and lymphocytes, decreased antibiotic use, and reduced infections by 60% in a phase 3 study.  The medication, which will be accessible to patients 12 years of age and up, targets a long-ignored area of immune disorders.  X4 Pharmaceuticals intends to keep advancing diagnostic efforts and training medical professionals.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global primary immunodeficiency disease market based on the below-mentioned segments: 

Global Primary Immunodeficiency Disease Market, By Disease

• Antibody Deficiency
• Cellular Immunodeficiency
• Innate Immune Disorders
• Others

Global Primary Immunodeficiency Disease Market, By Treatment

• Immunoglobulin Replacement Therapy
• Antibiotic Therapy
• Stem Cell/Bone Marrow Transplantation
• Gene Therapy
• Others

 Global Primary Immunodeficiency Disease Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa